Clinical Trials Logo

Advanced Solid Malignancies clinical trials

View clinical trials related to Advanced Solid Malignancies.

Filter by:

NCT ID: NCT06388902 Not yet recruiting - Clinical trials for Advanced Solid Malignancies

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

Start date: April 2024
Phase: Phase 1
Study type: Interventional

This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR115 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR115 for injection in patients with advanced solid malignancies. Patients will receive two doses at the first week of treatment, followed by once per week until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study.

NCT ID: NCT06028074 Recruiting - Clinical trials for Advanced Solid Malignancies

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Start date: December 12, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.

NCT ID: NCT05573724 Active, not recruiting - Clinical trials for Advanced Solid Malignancies

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Start date: November 7, 2022
Phase: Phase 1
Study type: Interventional

This study is a single-arm, open-label, multi-centre drug-drug interaction (DDI) study of AZD5305 administered orally in patients with advanced solid tumours.

NCT ID: NCT05469919 Active, not recruiting - Clinical trials for Advanced Solid Malignancies

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Start date: June 9, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ceralasertib in Japanese patients with advanced solid malignancies. Cycle 0 duration is 4 days and each cycle from Cycle 1 has a duration of 28 days.

NCT ID: NCT05417594 Recruiting - Clinical trials for Advanced Solid Malignancies

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

CERTIS1
Start date: June 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in 490 participants with advanced cancer that has recurred/progressed.

NCT ID: NCT05315167 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Start date: May 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in subjects with relapsed/refractory solid tumors. The study consists of two parts, one is a 3+3 dose escalation study and another is a pharmaceutical extension of RP2D.

NCT ID: NCT05159700 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Start date: March 31, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.

NCT ID: NCT04606381 Recruiting - Clinical trials for Advanced Solid Malignancies

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

PALOMA
Start date: November 10, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.

NCT ID: NCT04521413 Recruiting - Clinical trials for Advanced Solid Malignancies

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Start date: August 31, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.

NCT ID: NCT04353102 Completed - Clinical trials for Advanced Solid Malignancies

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

Start date: April 22, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation study of the study drug YH002. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH002 in patients with advanced solid Malignancies